INTRODUCTION
Lung cancer is the leading cause of cancer deaths worldwide with non-small cell lung cancer (NSCLC) being the most prevalent form of lung cancer [1] [2] [3] . Progress within the last decade has led to the sophisticated engineering and application of advanced preclinical models of human cancer in the mouse 4, 5 . These models are critical to our understanding of the human disease because they shed light on events and processes that cannot be easily studied using transplantable or chemically induced cancer models [5] [6] [7] . Several laboratories have constructed genetically engineered mouse models of NSCLC that mimic the genetic and histopathological features of the human disease 6, [8] [9] [10] [11] [12] [13] . The development of Cre recombinase-controlled (Cre/ LoxP) tumor models has allowed for the generation of autochthonous tumors derived from a limited number of somatic cells that become transformed in their natural location, surrounded by a normal tissue microenvironment 5 . By engineering LoxP DNA elements into the mouse genome that either surround ('flox') exons critical to a tumor suppressor gene's function or surround a synthetic 'stop' element (lox-stop-lox 'LSL') inserted in front of an oncogene, investigators can 'turn-off' tumor suppressors or 'turn-on' oncogenes with the delivery of Cre recombinase to the appropriate cell types (Supplementary Fig. 1 and see ref. 5 for a review of Cre/loxPcontrolled genetically engineered mouse models of cancer). With this technology, investigators can not only recapitulate the genetic alterations found in the human disease, but also the timing of onset and potentially the cellular origin of the disease.
Common mutations in human NSCLC are activating mutations in K-RAS (10%-30%) and loss of function point mutations in TRP53 (50%-70%) 2 . Our laboratory has modeled an oncogenic mutation in K-ras by changing a glycine to aspartic acid at codon 12 in the gene's endogenous locus. To control the expression of K-ras G12D , a LSL cassette was engineered into the first intron of the K-ras gene. The LSL cassette, which consists of transcriptional and translational stop elements flanked by LoxP sites, that prevents the expression of the mutant allele until the stop elements are removed by the activity of Cre recombinase 9, 14 . The LSL cassette thus creates a null version of the gene. It is important to note that K-ras null mice are embryonic lethal 15 ; therefore, mice can only be heterozygous for the K-ras LSL-G12D allele. To mimic the loss of p53 function in our K-ras LSL-G12D -driven tumor model, we have used a conditional p53 allele from the laboratory of Anton Berns. This 'floxed' p53 allele (p53 fl ) has LoxP sites flanking exons two through ten of p53 that are deleted after Cre-mediated recombination, abolishing p53 function 16 ( Supplementary Fig. 1 ). Before Cre-mediated recombination, the p53 locus is maintained in its wildtype state and p53 activity is normal. To more accurately recapitulate the p53 loss of function mutations commonly observed in human NSCLC, our laboratory has generated two conditional point mutant (mt) versions of p53 (R172H and R270H) that are engineered into the endogenous p53 locus, but silenced by a LSL cassette in the absence of Cre 17 . We use mice that are p53 LSL-mt/fl or p53 LSL-mt/+ to specifically express mutant p53 alone or with wildtype p53 (respectively) in tumors upon Cremediated recombination 17, 18 . It is important to note that, as with the K-ras LSL-G12D allele, the LSL cassette in p53 LSL-mt alleles blocks p53 expression in the absence of Cre, effectively creating a p53 null allele. Therefore, p53 LSL-mt/fl or p53 LSL-mt/+ mice are heterozygous for wildtype p53 and phenocopy p53 +/À mice. To specifically express or delete K-ras and p53 alleles sporadically in cells of the lung, mice inhale viruses engineered to express Cre either by intranasal instillation or intratracheal intubation.
Additional Cre recombinase controlled animal models of lung cancer In addition to the models of NSCLC used in this protocol, other conditional lung cancer models have been described that may be initiated with the inhalation of viruses expressing Cre. The activation of oncogenic K-ras along with loss of p16 Ink4a or Ink4a/Arf tumor suppressors, which are mutated in 20%-50% of human cases, have been described 11, 19 . In another mouse model, two other subtypes of NSCLC, squamous cell and large cell carcinoma, develop following the combined activation of oncogenic K-ras and loss of the LKB1 tumor suppressor, which is mutant in 10%-30% of human cases 19 . NSCLC models driven by p u o r G g n i h s i l b u P e r u t a Nconditionally activated mutations in Braf or epidermal growth factor (EGFR), mutated in 3% or 10%-40% (respectively) of human lung cancers, have also been generated 12, 13 (and unpublished data, K. Lane and T.J.). A model of small cell lung cancer (SCLC) has been created, in which tumors arise after the loss of both p53 and retinoblastoma (Rb) tumor suppressors 20 .
Limitations of viral delivery of Cre recombinase Although these Cre/LoxP models provide the most sophisticated means to sporadically control genetic events at their endogenous loci, they are also limited by the difficulty of introducing Cre into an initiating cancer cell. In this protocol, investigators cannot restrict the genetic events exclusively to initiating cells of the disease because of the inherently non-specific nature of the viruses used to deliver Cre to cells of the lung. However, this has in fact been beneficial in our laboratory because it does not require that investigators identify and target Cre specifically to the cell of origin of the disease. Perhaps the best system to deliver Cre specifically to the cells that give rise to the disease are the next generation regulatable Cre alleles, such as the tamoxifen-inducible Creestrogen receptor (Cre ERT ) fusion protein 5 . By expressing a Cre ERT transgene under the control of a cell type-specific promoter, investigators can induce Cre activity specifically in the cells of a given tissue by injecting animals with tamoxifen. With proper dosing of tamoxifen, investigators can in theory control the penetrance of Cre activity and therefore the multiplicity of the disease. However, various promoter-driven Cre ERT alleles are not yet available and Cre ERT models succumb to problems encountered with many transgenic models in that the expression and activity of these alleles are often leaky and do not provide tight control of tumor initiation in the organ of interest 5 . Therefore, despite the drawback of using potentially hazardous viruses, viral infection is the most effective means to sporadically deliver Cre to cells of the lung to initiate lung tumor formation.
Alternative animal models of lung cancer There are several alternative lung cancer models to those described here, which do not need viral delivery of Cre to the lungs to generate tumors (see ref. 6 for a comprehensive review of mouse models of NSCLC). Transgenic models have been created that use lung tissue specific promoters to drive the expression of viral oncoproteins, such as E6/E7 and large T antigen, or cellular oncogenes, such as c-myc, c-Raf-1 and v-H-ras 6 . However, these models are limited in recapitulating the human disease because the oncogenic transgene is expressed in all of the cells of a targeted organ beginning early in the organ's development. To overcome this limitation, our laboratory has engineered a latent oncogenic allele of K-ras that is expressed spontaneously in only a limited number of cells in the lung to initiate lung tumor formation 8 . However, the stochastic nature of this allele does not allow investigators to control tumor onset or multiplicity. Double transgenic models that rely on doxycycline-regulated transcriptional transactivators have allowed for the induction of oncogene expression in adult animals, making it possible to control tumor initiation 6 . However, these models still fail to provide sporadic oncogene expression at physiological levels due to the use of doxycyline-regulated transcription factors. Furthermore, these transgenic systems make it difficult to control tumor multiplicity and need continuous doxycycline dosing to maintain oncogene expression.
Applications of intranasal and intratracheal delivery methods
The intranasal and intratracheal infection techniques described in this protocol are not restricted to tumor-initiating studies. Investigators may theoretically probe the role of any Cre/LoxP-controlled genes in various cells of the lung using this protocol to deliver Cre. Alternatively, the intranasal or intratracheal delivery methods can be used in applications other than the viral delivery of Cre recombinase. The viral delivery systems may be adapted to express cDNAs or shRNAs in cells of the lung by infection with lentiviruses 21 . Viruses, such as the influenza virus, can be delivered for pathological studies 22 . Small interfering RNA (siRNAs) can be delivered as therapeutic agents for disease 23 . Although either the intranasal or intratracheal techniques can be used for the aforementioned studies, only intratracheal intubation is recommended for the orthotopic transplantation of lung tumor cells or lung tumor cell lines to the alveolar space of the lungs (unpublished data, C. Kim and T.J.). Certain chemical injurants, such as bleomycin, can be delivered intratracheally to study repair mechanisms in the lung and the effect of injury on tumor development 24 . Therefore, there are a number of uses of this technique for a variety of studies involving the mouse lung. Here we describe the use of the intranasal and intratracheal delivery methods to introduce viruses expressing Cre to initiate the K-ras LSL-G12D/+ (K) and the K-ras LSL-G12D/+ ;p53 fl/fl (KP) conditional mouse models of NSCLC ( Supplementary Fig. 1 ).
Experimental design
After deciding to use Cre/LoxP-controlled autochthonous tumor models, investigators must consider the genetic tumor model, the viral system to express Cre recombinase and the viral delivery method before initiating an experiment. Each option has certain advantages and limitations that are highlighted in the text and the tables. Other minor considerations such as anesthesia, age of mice and volume of virus are also discussed
Genetic model
Although both the K and KP NSCLC models induce tumors that resemble the human disease histopathologically, they have distinct features that make them more suitable for different applications ( Table 1) . In our laboratory's mouse models of NSCLC, the activation of an oncogenic allele of K-ras is sufficient to initiate the tumorigenesis process, whereas the additional deletion or point mutation of p53 significantly enhances tumor progression, leading to a more rapid development of adenocarcinomas that have features of a more advanced disease. KP tumors exhibit a greater incidence of cellular and nuclear pleomorphism, desmoplasia and a high frequency of metastases to the mediastinal lymph nodes and the pleural spaces of the thoracic cavity, and less frequently to the liver and kidneys.
Cre system
To generate tumors sporadically in the lungs of K-ras LSL-G12D/+ mice, our laboratory initially used replication-deficient adenoviruses expressing Cre (Ad-Cre) to deliver transient Cre expression to infected cells of the lung 9, 10 . Before administration, Ad-Cre is precipitated with calcium phosphate (see PROCEDURE) to improve the delivery of Cre by increasing the efficiency of viral infection of the lung epithelium 25 . Recently, we have used lentiviruses to deliver Cre to the lung (Lenti-Cre) 26 . Lentiviruses are beneficial because they integrate into the genome of infected cells 27 , allowing for further modification of the tumors by simultaneously introducing Cre recombinase and stable expression of cDNAs to overexpress, or short-hairpin RNAs to silence, genes of interest ( Table 2) .
To control for the number of tumors generated, viruses are titered before use in experiments. Ad-Cre is titered at the University of Iowa, whereas Lenti-Cre is titered in our laboratory by assaying for Cre activity after infection of the 3TZ reporter cell line, a mouse fibroblast cell line modified to express b-galactosidase after Cre-mediated recombination 28 . We infect mice with 2.5 Â 10 7 infectious particles of Ad-Cre or B10 4 -10 5 infectious particles of LentiCre. It is important to note that Ad-Cre and Lenti-Cre are titered differently, and as a result, the titers cannot be directly compared.
Viral administration method
Although we initially delivered Cre to the lungs of anesthetized mice using intranasal instillation of the virus, we now prefer to deliver the virus to the lungs by intratracheal intubation. Intratracheal delivery provides the most direct and consistent method for the virus to reach the lungs. Reproducible delivery of the virus is critical because it directly affects the number of tumors generated in the mice. However, intratracheal intubation needs additional equipment and practice to carry it out correctly and in a timely manner ( Table 3) . Therefore, it may be easier to begin with the intranasal delivery method to assess the tumor model and practice the intratracheal method while continuing to breed animals for future experiments.
Anesthesia
We recommend using avertin (2-2-2 Tribromoethanol) to anesthetize the mice. The amount of avertin administered to the mice is crucial to the success of the procedure. Mice administered with too much avertin are more likely to stop breathing during the infection procedure and recover poorly from the anesthesia. Conversely, mice administered with too little avertin may struggle to inhale the virus and should be given more avertin before continuing. Therefore, we recommend using the smallest volume of avertin needed to keep mice anesthetized during the procedure. Following the procedure, mice will recover better if they are kept warm to maintain their normal body temperature after anesthesia.
Age of mice
Our laboratory has utilized mice between 6 and 12 weeks of age for tumor initiation by intranasal or intratracheal delivery of viruses expressing Cre. Mice of this age are old enough to recover from the anesthetic, the volume of virus administered to the lung and the intubation of the trachea with the catheter.
Volume of virus
Mice can be infected with a volume ranging from 50 ml to 125 ml per mouse, but we recommend using a total volume of 75 ml per mouse. Although a volume of 125 ml can be administered, it is not recommended for very young mice (6 weeks of age or younger). If 125 ml is administered, then the mice should receive two doses of 62.5 ml each, with a 1-5 min break in between the doses, to allow the mice to recover a normal breathing pattern before receiving the second dose.
MATERIALS
REAGENTS m CRITICAL The following list of reagents represents our laboratory's preference. All reagents, with the exception of Ad-Cre, can be modified according to investigator preference. (Fig. 1a) .
Insert the catheter into the trachea outside the hood, and then move the mouse into the biosafety hood to inhale the virus. A sharps waste container is also needed for the proper disposal of the needles from the Exel Safelet IV catheter.
PROCEDURE Virus preparation TIMING 30 min
1| For infection with Lenti-Cre, proceed to Step 5. For Ad-Cre, prepare the adenovirus-precipitate mixture. Determine the number of mice that need to be infected and pipette the appropriate volume of MEM into a tube. Refer to the Experimental design section to determine the volume of virus to administer per mouse. ! CAUTION Preparation and administration of viruses should occur in a biosafety hood and follow all guidelines for biosafety level 2 research. Research with lentiviruses pseudotyped with VSV-G containing known or putative oncogenes or short hairpin RNAs to silence tumor suppressor genes should abide by institute safety practices. ! CAUTION All experiments should be carried out in accordance with protocols approved by the Institutional Animal Care and Use Committee. m CRITICAL STEP The adenovirus-precipitate mixture should be used within 1 h of preparation. If many mice will be infected, precipitates should be prepared sequentially.
2| After the adenovirus thaws on ice, pipette the adenovirus directly into the MEM to obtain a final titer of 2.5 Â 10 7 PFU per mouse. Flick the tube to mix. m CRITICAL STEP Do not freeze/thaw the adenovirus as this reduces the titer of the virus tenfold with each thaw. (i) Place the mouse on the platform so that it is hanging from its top front teeth on the bar (Fig. 1a-c) .
(ii) Push the mouse towards the bar so that the chest is vertical underneath the bar (perpendicular to the platform) (Fig. 1b) . (Fig. 1b,c) . (iv) Prepare the Exel Safelet IV catheter for the infection procedure. To ensure that the needle does not become exposed and impale the mouse, hold the square part of the needle with the thumb and the index finger, and using the middle finger, push the catheter over the end of the needle completely and continue to hold the catheter in place during the infection protocol ( Supplementary Fig. 2a,b) . ? TROUBLESHOOTING (v) Using the Exel Safelet IV catheter, open the mouth and gently pull out the tongue with the flat forceps (Fig. 1d) . (vi) Locate the opening of the trachea by peering into the mouth and looking for the white light emitted from the trachea (Fig. 1e) .
? TROUBLESHOOTING (vii) While holding the Exel Safelet IV catheter vertically, position the catheter over the white light emitted from the opening of the trachea, and allow the catheter to slide into the trachea until the top of the catheter reaches the mouse's front teeth (Fig. 1f) . There should be no resistance while inserting the catheter into the trachea. (viii) While stabilizing the Exel Safelet IV catheter with one hand, remove the needle from the mouth (Fig. 1g) . m CRITICAL STEP Before removing the needle, the mouse cannot breathe through the catheter. Once the Exel Safelet IV catheter has been inserted into the trachea, promptly remove the needle to allow the mouse to breathe through the catheter. (ix) The proper placement of the catheter in the trachea can be confirmed by visualizing the white light shining through the opening of the catheter in the mouth (Fig. 1h) . (x) Move the platform, mouse and catheter into the biosafety hood. (xi) Pipette the virus directly into the opening of the catheter to ensure the entire volume is inhaled (Fig. 1i) . (xii) If the catheter is correctly inserted into the trachea, the mouse will begin inhaling the virus immediately. Once the virus is no longer visible in the opening of the catheter, wait a few seconds for the entire volume to travel down the catheter before removing the catheter from the trachea and disposing of it in 50% bleach. ? TROUBLESHOOTING (B) Delivery of Ad-Cre or Lenti-Cre using the intranasal delivery method TIMING 2-5 min per mouse (i) In the biosafety hood, lay the mouse in your hand, ventral side up. Tilt the mouse so that the head is positioned above its feet (Fig. 2a) . m CRITICAL STEP Do not grasp the mouse tightly, as this will inhibit the mouse's breathing. The mouth is opened using the Exel Safelet IV catheter (d), and the tongue is gently pulled out using the flat forceps. After locating the white light emitted from the trachea (e), the Exel Safelet IV catheter is slid into the trachea (f), and the needle is removed (g). The mouse with the inserted catheter (h) on the platform is moved into a biosafety hood, where the virus is dispensed into the opening of the catheter (i). ! CAUTION All experiments should be done in accordance with protocols approved by the Institutional Animal Care and Use Committee. (ii) Hold the end of a pipette tip over the opening of one nostril and dispense the virus dropwise until the entire volume of virus has been inhaled (Fig. 2b,c) . m CRITICAL STEP Do not attempt to insert the pipette tip into the nostril. ? TROUBLESHOOTING Animal recovery TIMING 10-15 min 7| Place the mouse under a heat lamp ( Supplementary Fig. 3a) or on a latex glove filled with warm water ( Supplementary  Fig. 3b ) to recover in the biosafety hood.
? TROUBLESHOOTING
TIMING
Steps 1-4, Virus preparation (Ad-Cre only): 30 min
Step 5, Avertin administration: 5 min per mouse
Step 6A, Intratracheal infection: 1-5 min per mouse after an initial training phase
Step 6B, Intranasal delivery: 2-5 min per mouse
Step 7, Animal recovery: 10-15 min
? TROUBLESHOOTING Troubleshooting advice can be found in Table 4 .
ANTICIPATED RESULTS
We have reported that recombination of K-ras LSL-G12D and p53 fl alleles in tumors can be examined by PCR for the presence of a '1 lox', or recombined, product (see Reagents in Materials section for the protocols) 9 . Although it is possible to carry out PCR on DNA isolated from whole lung after infection to assess infection efficiency, this is not recommended. Step Problem Possible reason Solution 5
Mouse is not falling asleep Not enough avertin administered Administer more avertin, 50 ml-100 ml at a time
Mouse is over-anesthetized and breathing very slowly Too much avertin administered Wait until breathing becomes more regular but ensure the mouse still lacks a reflex response before attempting to infect the mouse 6A(iv) Blood appears in mouth Catheter has slipped and exposed the needle Make sure that the catheter is held in place to cover the needle correctly ( Supplementary Fig. 2a Mouse is too cold Mouse should be kept warm until it starts to wake up
Mouse is too hot under heat lamp Turn off heat lamp temporarily or let mouse recover on a glove filled with warm water the lung have undergone recombination of these alleles, making it difficult to detect recombination. Instead, it is more informative to examine Cre expression after infection by using conditional reporter strains such as Rosa26 LSL-LacZ or Rosa26 LSL-eGFP and examining reporter expression by immunohistochemistry, immunofluorescence or fluorescent activated cell sorting 33 . Polyclonal antibodies that can specifically detect the oncogenic K-ras G12D protein are no longer available; however, increased Ras-GTP levels in tumors or cells can be assessed using a Raf-GST pulldown assay 14 .
The time to tumor development and progression will vary depending upon the model chosen (K vs. KP), whereas survival time will also depend on the amount and type of virus administered to the mice. The survival of mice is reduced approximately twofold in KP mice compared with K mice (median survival with Ad-Cre: K, 185 d; KP, 76 d, with Lenti-Cre: K, 266 d; KP, 170 d) (Fig. 3a,b) . Survival is decreased because of a greater growth rate of tumors lacking p53, leading to the more rapid development of a tumor burden that disrupts the normal function of the lungs. Reduced survival after p53 loss is not because of an increased number of tumors or metastatic disease. Survival of mice is also reduced after infection with Ad-Cre as compared with Lenti-Cre (Fig. 3a,b) . This is due to the higher titer of virus typically administered to mice with Ad-Cre, but may also reflect the viral tropism or the efficiency of the virus to infect the cell of origin of the disease. Mice infected with 2.5Â10 7 infectious particles of Ad-Cre (University of Iowa, Gene Transfer Vector Core) can generate greater than 200 tumors per mouse, whereas mice infected with roughly 10 4 to 10 5 infectious particles of Lenti-Cre (3TZ titered) can generate 10-100 tumors per mouse. Our laboratory has had success titrating the viruses to lower levels (Ad-Cre: 5Â10 6 infectious particles per mouse, Lenti-Cre: 5Â10 3 infectious particles per mouse), which reduce the number of primary tumors and increase the survival time of mice, allowing for a greater frequency of metastatic disease in the KP model. Monitoring tumor development and progression histologically is an important, though difficult, way to follow the disease, and it is especially useful in experiments where genetic events or modifications in addition to K-ras activation and/or p53 loss may be expected to effect tumor progression. We stress that the NSCLC model generates a multi-focal disease and therefore, investigators should expect some tumor heterogeneity; tumors do not always progress in exactly the same way or at the same time. To follow these changes objectively, we have employed a four-stage grading system for tumor progression in our NSCLC models (adapted from ref. 18 ). The earliest lesions, designated as grade 1, are atypical adenomatous hyperpasias (AAH) or small adenomas that feature uniform nuclei and can appear as early as 2 to 3 weeks post-infection (Fig. 4a) . These earliest lesions can only be identified through careful histological analysis. To see visible lesions on the surface of the lung, investigators should wait until 6-8 weeks after tumor initiation or later. Grade 2 tumors are larger adenomas that have slightly enlarged nuclei with prominent nucleoli and are observed 6-8 weeks post-infection (Fig. 4b,c) . Adenocarcinomas are classified as grade 3; they have a great degree of cellular pleomorphism and nuclear atypia and can develop as early as 16 weeks post-infection (Fig. 4d,e) . Grade 4 tumors are invasive adenocarcinomas (Fig. 4f) that harbor all the cellular characteristics of grade 3 tumors, but with a higher mitotic index-including irregular mitoses, a distinctive highly invasive stromal reaction (desmoplasia) (Fig. 4g) , and invasive edges bordering lymphatic vessels, blood vessels or the pleura (Fig. 4h) . Grade 4 tumors may develop as early as 18 weeks post-infection in KP animals, but are not observed in K animals. Finally, locally metastatic disease to the mediastinal lymph nodes (Fig. 4i) or the pleural cavity develops in B50% of KP mice as early as 18-20 weeks post-infection. In some mice, distant metastases can be found seeding the liver or the kidneys as early as 20 weeks post-infection (Fig. 4j) . Although the time to progression in K and KP mice is described here to be similar up to grade 3 lesions, mice with p53 deficient tumors often harbor cells that exhibit nuclear atypia at very early time points after tumor initiation. In addition, a greater proportion of tumors that lack p53 progress to higher grades during tumor development 18 . For example, at 6 weeks after infection the distribution of tumor grades in the K model is B90% grade 1 and B10% grade 2, whereas in the KP model it is B40% grade 1, B40% grade 2 and B20% grade 3 (ref. 
